CYTOPRO
Profiling of tumour cells in blood for personalized treatment of metastatic cancer
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0CYTOPRO project word cloud
Explore the words cloud of the CYTOPRO project. It provides you a very rough idea of what is the project "CYTOPRO" about.
Project "CYTOPRO" data sheet
The following table provides information about the project.
| Coordinator |
CYTOTRACK APS
Organization address contact info |
| Coordinator Country | Denmark [DK] |
| Project website | http://www.cytotrack.com |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SMEINST-1-2015 |
| Funding Scheme | SME-1 |
| Starting year | 2015 |
| Duration (year-month-day) | from 2015-10-01 to 2015-10-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | CYTOTRACK APS | DK (LYNGBY) | coordinator | 50˙000.00 |
Map
Project objective
Challenge Up to 40% of patients diagnosed with metastasised breast cancer fail to respond to treatment. Cancer cost the EU €126bn in 2009 incl. productivity losses of €42.6bn and lost working days worth €9.43bn. 3.2m citizens in EU lose their lives to cancer each year.
Solution Circulating Tumour Cells (CTC) are cells that have shed into the vasculature from a primary tumour and circulate in the bloodstream. CytoTrack has developed a breakthrough technology that can identify and isolate metastatic cancer cells from a blood sample. It is superior to all other technologies due to a very efficient and non-biased detection principle and an integrated feature to isolate individual cells for characterisation. It is the perfect tool to be used together with new single cell characterisation assays currently being introduced on the market.
Impact The innovation will provide an effective, accurate, fast and cheap characterisation of CTCs in a single device, enabling pathologists and clinicians worldwide to deliver personalised medicine and cancer treatment targeted the exact mutation of the individual patient’s cancer form. CytoTrack expects that the innovation can reduce cancer deaths by 10%. In EU alone this would reduce the productivity loss with >€10bn per year and treatment costs with >€12.5bn.
Project This phase 1 project will investigate 1) collaboration with labs, 2) regulatory conditions for first markets, and 3) prepare for clinical trials. The overall innovation project will enable CytoTrack to be the first on the market to offer an integrated diagnostic platform for routine isolation and characterisation of metastatic cancer cells in blood, enabling personalised therapy targeting the exact profile of the cancer form.
Customers and market The CTC technology market was $3.7bn in 2013, growing 18.9% annually. The research market is a first step in gaining a strong foothold before approaching the much larger, but also more challenging, clinical market.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CYTOPRO" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CYTOPRO" are provided by the European Opendata Portal: CORDIS opendata.
More projects from the same programme (H2020-EU.3.1.3.)
RESHAPE (2019)
Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials
Read More